Eye drops containing a derivative of turmeric reduce the loss of retinal cells in rats, finds a new study led by UCL and Imperial College London researchers.
Loss of these cells is known to be an early sign of glaucoma and the eye drops could in time be a new treatment option for the condition.
In the new Scientific Reports paper, the researchers report a new method to deliver curcumin, extracted from the yellow spice turmeric, directly to the back of the eye using eye drops, overcoming the challenge of curcumin’s poor solubility.
They are also investigating how the eye drops could be used as a diagnostic tool for a range of conditions.
“Curcumin is an exciting compound that has shown promise at detecting and treating the neurodegeneration implicated in numerous eye and brain conditions from glaucoma to Alzheimer’s disease, so being able to administer it easily in eye drops may end up helping millions of people,” said the study’s lead author, Professor Francesca Cordeiro (UCL Institute of Ophthalmology, Western Eye Hospital and Imperial College London).
Glaucoma is a group of eye conditions affecting over 60 million people worldwide that leads to irreversible blindness in 1 in 10 cases. The condition mainly involves the loss of retinal ganglion cells, a type of neuron located near the surface of the retina. Stopping the loss of these cells early on has not yet been achieved, so it is a key focus of glaucoma research.
Curcumin has previously been shown to protect retinal ganglion cells when administered orally. For the current study, the researchers were seeking to find a more reliable method to deliver curcumin. Oral administration is difficult because curcumin has poor solubility, so it does not easily dissolve and get absorbed into the bloodstream, and would require people to take large amounts of tablets (up to 24 a day) that may cause gastrointestinal side effects.
The team developed a novel nanocarrier, wherein the curcumin is contained within a surfactant combined with a stabiliser, both of which are known to be safe for human use and are already in existing eye products. The nanocarrier can be used in eye drops to deliver much higher loads of curcumin than other products in development, increasing the drug’s solubility by a factor of almost 400,000, and localises the curcumin in the eyes instead of throughout the body.
The researchers initially tested the product on cells that are used to model glaucoma, before conducting trials in rats with eye conditions involving the loss of retinal ganglion cells.
After twice-daily use of eye drops in the rats for three weeks, retinal ganglion cell loss was significantly reduced compared to matched controls, and the treatment was found to be well-tolerated with no signs of eye irritation or inflammation.
Having found an effective way to deliver curcumin, the researchers are hopeful that it could also be used to diagnose Alzheimer’s disease, as curcumin is known to bind to the amyloid beta protein deposits implicated in Alzheimer’s, and can be detected in the retina with fluorescence to highlight the malignant proteins.
“We are now researching diagnostic uses for these eye drops alongside other ways to visualise the retina, as eye tests can be an opportunity to detect signs of neurodegeneration with a simple, non-invasive test,” said co-lead author Dr Ben Davis (UCL Institute of Ophthalmology and Imperial College London).
Professor Cordeiro added: “As we live longer, diseases such as glaucoma and Alzheimer’s are steadily increasing. We believe our findings could make a major contribution at helping the lives of people affected by these devastating diseases.”
The Latest on: Glaucoma
via Google News
The Latest on: Glaucoma
- Tao the blind golden retriever needs 'guide human' to help him around after losing eyes to glaucomaon March 19, 2020 at 7:03 am
This adorable golden retriever looks like a guide dog but is actually blind - and needs a 'guide human' to help it get around. Tao had both eyes removed due to glaucoma over two operations - the ...
- Trend In Anti-glaucoma Drug Market Is Now Ready To Analysis For Market Size, Segment, Share & Opportunity Forecast To 2026on March 16, 2020 at 4:29 am
An exhaustive review has been conducted that consists of the latest trends and modes prevalent in the industry. The global Anti-glaucoma Drug Market consists of a brief informative overview, that ...
- Global Glaucoma and Cataract Surgery Devices Market Research Report | Johnson & Johnson, Alcon Inc and New World Medical Incon March 16, 2020 at 4:17 am
Global Glaucoma and Cataract Surgery Devices Market (Revenue and Volume), Type, Application, End-User, and Regional Analysis, Import-Export Analysis, Industry Analysis, Premium Insights, Intellectual ...
- Glaucoma after ocular chemical burns: Incidence, risk factors, and outcomeon March 16, 2020 at 3:50 am
Effects of chemical injuries on the cornea and limbus have been widely studied; however, little is known about glaucoma after ocular chemical injuries. We herein investigated the incidence, risk ...
- Regular eye screening can prevent glaucomaon March 15, 2020 at 11:59 am
Glaucoma is a disease that damages the optic nerve that connects the eye to the brain, usually due to high eye pressure. It normally happens when fluid builds up in the front part of the eye. The ...
- Igbos at higher risk of glaucoma blindness ― Govt Surveyon March 15, 2020 at 11:50 am
A Federal Government-backed survey on the prevalence of glaucoma in Nigeria has revealed that the people of the Southeast region are at greater risk of blindness resulting from glaucoma than any other ...
- World Glaucoma Day: Optometrists caution against self-medication on eye disorderon March 12, 2020 at 8:00 pm
NOA state Chairman, Dr. Chigozie Umeh made the call at the inauguration of free eye screening against glaucoma at J. Ropheka Eye Clinic, Nkpor near Onitsha on Thursday. According to him, some of the ...
- ‘Early diagnosis of glaucoma could prevent blindness’on March 12, 2020 at 11:30 am
As glaucoma is a silent eye disease that affects the visual nerves resulting in blindness, early detection and treatment could prevent loss of vision, said doctors here on Thursday. As part of World ...
- Fight for Sight funded researcher develops gene therapy approach for glaucomaon March 11, 2020 at 6:14 pm
A Fight for Sight funded researcher from the University of Bristol has used gene editing techniques to successfully demonstrate a gene therapy for glaucoma in the lab, in results published in ...
via Bing News